Since PCa treated with ADT eventually switch to an androgen refractory state, where cells express survival genes bypassing hormone-dependent AR recruitment, myosin VI has been suggested as a potential therapeutic target for PCa, given that it acts as a regulator element able to interact with AR and affect AR-dependent protein levels. The gene discussed is AR; the disease is posterior cortical atrophy.